Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share [Seeking Alpha]
Kinnate Biopharma Inc. (KNTE)
Company Research
Source: Seeking Alpha
Kinnate Biopharma ( NASDAQ: KNTE ) for $2.3352–$2.5879 per share in cash plus a contingent value right. Per the terms, the deal indicates a base price of $2.3352 per share and an additional per-share cash value not exceeding $0.2527 at the close. The non-transferable CVR allows KNTE stockholders to receive 85% of the net proceeds from any out-licensing or sale transactions related to Kinnate programs completed within one year of the merger. They can receive 100% of the net proceeds if out-licensing or sale transactions conclude before the deal closes. In connection with the acquisition, XOMA ( XOMA ) is expected to start a tender offer on March 4, 2024, to acquire all outstanding shares of Kinnate ( KNTE ) common stock. Following the successful conclusion of the tender offer, Kinnate ( KNTE ) is set to merge with a subsidiary of XOMA ( XOMA ). The deal is expected to close in April 2024. More on Kinnate Biopharma, XOMA, etc. Recommended For You Recommended For You Relate
Show less
Read more
Impact Snapshot
Event Time:
KNTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNTE alerts
High impacting Kinnate Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
KNTE
News
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, DOOR, HMSTGlobeNewswire
- KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEBusiness Wire
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - EVBG, TAST, ZFOX, KNTEPR Newswire
- XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]Yahoo! Finance
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - KNTE, INBX, KAMNAccesswire
KNTE
Earnings
- 11/9/23 - Beat
KNTE
Sec Filings
- 4/3/24 - Form S-8
- 4/3/24 - Form S-8
- 4/3/24 - Form S-8
- KNTE's page on the SEC website